BACTROBAN CREAM

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

MUPIROCIN (MUPIROCIN CALCIUM)

제공처:

GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC

ATC 코드:

D06AX09

INN (국제 이름):

MUPIROCIN

복용량:

2%

약제 형태:

CREAM

구성:

MUPIROCIN (MUPIROCIN CALCIUM) 2%

관리 경로:

TOPICAL

패키지 단위:

15G

처방전 유형:

OTC

치료 영역:

ANTIBIOTICS

제품 요약:

Active ingredient group (AIG) number: 0117081001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2020-07-24

제품 특성 요약

_ _
_Product Monograph: _
_July 6, 2016_
_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
BACTROBAN
® CREAM
Mupirocin Cream USP 2% (w/w) as mupirocin calcium
TOPICAL ANTIBIOTIC
GlaxoSmithKline Consumer Healthcare Inc
7333 Mississauga Road North
Mississauga, Ontario
L5N 6L4
Date of Preparation:
July 6, 2016
Submission Control No: 194464
® Bactroban is a registered trademark, used under license by
GlaxoSmithKline Consumer Healthcare Inc.
_ _
_Product Monograph: _
_July 6, 2016_
_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
..........................................................................................10
SPECIAL HANDLING INSTRUCTIONS
.......................................................................10
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEU